Singlomics Biopharmaceuticals Zhuhai

Singlomics Biopharmaceuticals is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies using high-throughput single-cell sequencing technologies. Founded by renowned scientist Dr. Sunney Xie, the company leverages its proprietary ALECTM platform to rapidly identify potent neutralizing antibodies from convalescent patients and "super-responders." Singlomics gained international prominence for its rapid development of COVID-19 neutralizing antibodies, DXP-593 and DXP-604, in collaboration with BeiGene and Peking University. Beyond infectious diseases, the company is advancing a robust pipeline of monoclonal and bispecific antibodies targeting oncology and autoimmune disorders, including programs focused on IL-1RAP and TREM-1.